Cardio Diagnostics Holdings, Inc., a leader in epigenetics and AI-driven precision cardiovascular medicine, has entered into a strategic agreement with Aimil Ltd. and Dr. Lal PathLabs to launch its PrecisionCHD test in India. Through this collaboration, the partners aim to transform the detection and management of coronary heart disease (CHD) across the country.
First International Expansion for Cardio Diagnostics
This partnership marks Cardio Diagnostics’ first expansion beyond the United States and its official entry into the Indian market. Importantly, the move brings advanced molecular diagnostics to India, where cardiovascular disease remains a leading and growing public health challenge. Studies indicate that CHD prevalence in India ranges from up to 7.4 per cent in rural areas to as high as 13 per cent in urban populations.
PrecisionCHD Brings Molecular-Level Detection of Heart Disease
PrecisionCHD is a clinically validated blood test that detects coronary heart disease at the molecular level by integrating epigenetics, genetics, and artificial intelligence. As a result, the test provides actionable insights that help physicians identify the key molecular drivers of disease, enabling more personalised treatment and ongoing management.
Beyond detecting obstructive CHD—commonly identified through angiograms—PrecisionCHD can also identify non-obstructive CHD, which angiograms often fail to detect. Supporting data on its ability to detect ischemia with no obstructive coronary arteries (INOCA) and myocardial infarction with no obstructive coronary arteries (MINOCA) were recently presented at the American Heart Association Scientific Sessions in New Orleans.
Phased Rollout Through Dr. Lal PathLabs Network
As reported by pharmabiz, the initial phase of the partnership has already begun and focuses on integrating and promoting PrecisionCHD within Dr. Lal PathLabs’ extensive laboratory and clinical network. During this phase, the partners will ensure alignment with Indian clinical practices and regulatory requirements. Subsequently, the collaboration will move toward a full commercial rollout, which is expected in 2026.
Leadership Highlights the Impact of the Collaboration
Commenting on the development, Dr. Meesha Dogan, CEO and Co-founder of Cardio Diagnostics, said the partnership represents a major step in democratising access to advanced cardiovascular diagnostics. She added that the collaboration reflects the company’s ongoing efforts to expand the reach of its technology beyond the US market.
Dr. Mallika Kapur, Executive Director of Aimil, noted that partnering with Cardio Diagnostics and Dr. Lal PathLabs will enable the delivery of cutting-edge cardiovascular diagnostics capable of transforming how heart disease is detected and managed in India. She emphasised that the collaboration reinforces Aimil’s long-standing commitment to bringing world-class medical technologies to the Indian healthcare ecosystem.
Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs Ltd., stated that the partnership aligns closely with the company’s mission to provide patients, cardiologists, and physicians with the most advanced and reliable diagnostic solutions. By integrating molecular-level detection of coronary heart disease, he said, the company can help clinicians identify disease earlier and support more effective, personalised treatment strategies.
Strengthening Precision Medicine in India
Overall, this expansion underscores Cardio Diagnostics’ commitment to advancing precision cardiovascular medicine globally. At the same time, it addresses the urgent need for earlier detection and improved management of heart disease in one of the world’s most populous regions.
About the Partners
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalised, and precise.
Founded in 1932, Aimil Ltd. specialises in introducing leading-edge technologies to India. With 14 sales and service offices, over 1,000 employees, NABL-certified testing and calibration laboratories, and in-house manufacturing, R&D, and software development capabilities, Aimil supports overseas companies seeking to expand professionally in India.
Dr. Lal PathLabs Limited is one of India’s premier providers of diagnostic and healthcare-related services. Headquartered in Delhi NCR, the company operates a vast network of clinical laboratories, collection centres, and pick-up points, delivering accurate and timely diagnostic solutions to millions of patients each year.